Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zn-Telomir · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Phase I Dose Escalation | EXPERIMENTAL | Participants receive oral Zn-Telomir once daily on Days 1-14 of each 28-day cycle at assigned cohort dose levels of 50 mg, 100 mg, 150 mg, 200 mg, 300 mg, or 400 mg. Number of cycles will vary based on dose level and tolerability. |
| Phase II Dose Expansion | EXPERIMENTAL | Participants receive oral Zn-Telomir at the recommended Phase II dose once daily on Days 1-14 of each 28-day cycle for up to 4 cycles, if tolerated. |
| Name | Type | Description |
|---|---|---|
| Zn-Telomir | DRUG | Zn-Telomir is an oral small molecule that inhibits iron-dependent KDM enzymes, reduces tumor DNA methylation, and kills cancer cells in an iron-dependent manner - targeting epigenetic and metal homeostasis drivers of cancer cell survival. |
Inclusion Criteria: 1. Clinically defined histologically or cytologically confirmed triple-negative breast cancer (TNBC) 2. Locally advanced unresectable or metastatic disease 3. Must have completed prior anticancer therapy discontinued for a least 28 days 4. Disease progression after prior systemi...
Zn-Telomir is an investigational small molecule being developed by Telomir Pharmaceuticals, Inc. (ticker TELO) as an oral monotherapy for advanced or metastatic triple-negative breast cancer (TNBC). It is in Phase 1 clinical development and is not yet approved for any use.
Zn-Telomir is being studied as an oral monotherapy for patients with advanced or metastatic triple-negative breast cancer (TNBC). The Phase 1 trial enrolls adults aged 18 years and older with these conditions. Because it remains investigational, no approved use in TNBC or any other indication has been established.
Zn-Telomir is developed by Telomir Pharmaceuticals, Inc., which trades under the ticker TELO. The company is the sponsor of the clinical program evaluating the drug in triple-negative breast cancer.
Zn-Telomir is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. The program currently has one Phase 1 trial, which is active but not yet recruiting participants.
Zn-Telomir is being evaluated in one Phase 1 trial, NCT07581314, titled Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC). The trial has a controlled design, is not yet recruiting, and plans to enroll 76 participants aged 18 years and older.
Yes. The Phase 1 trial of Zn-Telomir, NCT07581314, is biomarker selected, meaning enrollment is guided by a biomarker rather than an unselected patient population. The study evaluates oral Zn-Telomir monotherapy in adults with advanced or metastatic triple-negative breast cancer and plans to enroll 76 participants.